The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
920
April 15, 1994
View Complete Issue         Table of Contents 2019 
Ophthalmic Levocabastine for Allergic Conjunctivitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ophthalmic Levocabastine for Allergic Conjunctivitis
April 15, 1994 (Issue: 920)
A 0.05% ophthalmic solution of levocabastine hydrochloride (Livostin - Iolab), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic conjunctivitis. The new drug is a...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ophthalmic Levocabastine for Allergic Conjunctivitis
Article code: 920c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.